Literature DB >> 25755699

MOK overexpression is associated with promoter hypomethylation in patients with acute myeloid leukemia.

Jun Qian1, Qin Chen2, Dong-Ming Yao2, Lei Yang1, Jing Yang1, Xiang-Mei Wen2, Ying-Ying Zhang1, Hai-Yan Chai1, Ji-Chun Ma2, Zhao-Qun Deng2, Jiang Lin2.   

Abstract

Overexpression of MAPK/MAK/MRK overlapping kinase (MOK) has been found in various tumors. However, the mechanism underlying MOK upregulation remains unclear. A CpG island was identified in MOK promoter. In this study, we evaluated the expression and methylation status of MOK gene in acute myeloid leukemia (AML). Hypomethylation of MOK promoter was detected in 31.0% (45/145) of AML patients. The degree of MOK hypomethylation was significantly correlated with MOK expression in AML patients. MOK-hypomethylated patients had a trend towards lower WBCs. Receiver operating characteristic curve (ROC) analysis showed a good performance in distinguishing AML patients from controls with an area under the ROC curve (AUC) of 0.820 (P < 0.001). In summary, our results suggest MOK promoter hypomethylation is a common event and contributes to MOK overexpression in AML.

Entities:  

Keywords:  MOK; acute myeloid leukemia; hypomethylation

Mesh:

Substances:

Year:  2015        PMID: 25755699      PMCID: PMC4348826     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  30 in total

1.  Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.

Authors:  Frederic J Reu; Soo In Bae; Leonid Cherkassky; Douglas W Leaman; Daniel Lindner; Normand Beaulieu; A Robert MacLeod; Ernest C Borden
Journal:  J Clin Oncol       Date:  2006-06-26       Impact factor: 44.544

2.  The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia.

Authors:  Barbara-Ann Guinn; Amanda F Gilkes; Ghulam J Mufti; Alan K Burnett; Ken I Mills
Journal:  Br J Haematol       Date:  2006-07       Impact factor: 6.998

3.  Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia.

Authors:  Barbara-Ann Guinn; Amanda F Gilkes; Eleanor Woodward; Nigel B Westwood; Ghulam J Mufti; David Linch; Alan K Burnett; Ken I Mills
Journal:  Biochem Biophys Res Commun       Date:  2005-08-05       Impact factor: 3.575

4.  Generation of RAGE-1 and MAGE-9 peptide-specific cytotoxic T-lymphocyte lines for transfer in patients with renal cell carcinoma.

Authors:  Nicole Oehlrich; Gerard Devitt; Michael Linnebacher; Yvette Schwitalle; Sonja Grosskinski; Stefan Stevanovic; Margot Zöller
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

5.  Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia.

Authors:  Oliver Galm; Stefan Wilop; Christian Lüders; Edgar Jost; Gerald Gehbauer; James G Herman; Rainhardt Osieka
Journal:  Ann Hematol       Date:  2005-12       Impact factor: 3.673

Review 6.  Cancer/testis antigens, gametogenesis and cancer.

Authors:  Andrew J G Simpson; Otavia L Caballero; Achim Jungbluth; Yao-Tseng Chen; Lloyd J Old
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

7.  Tumor-associated antigens as possible targets for immune therapy in head and neck cancer: comparative mRNA expression analysis of RAGE and GAGE genes.

Authors:  Karl Götte; Dirk Usener; Frank Riedel; Karl Hörmann; Dirk Schadendorf; Stefan Eichmüller
Journal:  Acta Otolaryngol       Date:  2002-07       Impact factor: 1.494

8.  A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.

Authors:  B Gaugler; N Brouwenstijn; V Vantomme; J P Szikora; C W Van der Spek; J J Patard; T Boon; P Schrier; B J Van den Eynde
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

9.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Authors:  D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

10.  mRNA expression of tumor-associated antigens in melanoma tissues and cell lines.

Authors:  Stefan Eichmüller; Dirk Usener; Anita Jochim; Dirk Schadendorf
Journal:  Exp Dermatol       Date:  2002-08       Impact factor: 3.960

View more
  4 in total

1.  Demethylation of tumor necrosis factor-α converting enzyme promoter associated with high hepatitis B e antigen level in chronic hepatitis B.

Authors:  Zhen-Li Wang; Shuai Gao; Xin-You Li; Feng-Kai Sun; Feng Li; Yu-Chen Fan; Kai Wang
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

2.  Prognostic Classifier Based on Genome-Wide DNA Methylation Profiling in Well-Differentiated Thyroid Tumors.

Authors:  Mariana Bisarro Dos Reis; Mateus Camargo Barros-Filho; Fábio Albuquerque Marchi; Caroline Moraes Beltrami; Hellen Kuasne; Clóvis Antônio Lopes Pinto; Srikant Ambatipudi; Zdenko Herceg; Luiz Paulo Kowalski; Silvia Regina Rogatto
Journal:  J Clin Endocrinol Metab       Date:  2017-11-01       Impact factor: 5.958

3.  Downregulation of mapk/mak/mrk overlapping kinase 1 in peripheral blood mononuclear cells of pediatric patients with type 1 diabetes mellitus.

Authors:  Miron Sopić; Ana Ninić; Barbara Ostanek; Dragana Bojanin; Tatjana Milenković; Jelena Munjas; Marija Mihajlović; Jelena Vekić; Janja Marc; Vesna Spasojević-Kalimanovska
Journal:  J Med Biochem       Date:  2022-07-29       Impact factor: 2.157

4.  The A to I editing landscape in melanoma and its relation to clinical outcome.

Authors:  Austeja Amweg; Marina Tusup; Phil Cheng; Ernesto Picardi; Reinhard Dummer; Mitchell P Levesque; Lars E French; Emmanuella Guenova; Severin Läuchli; Thomas Kundig; Mark Mellett; Steve Pascolo
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.766

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.